Neurogene (NASDAQ:NGNE) Research Coverage Started at BMO Capital Markets

BMO Capital Markets started coverage on shares of Neurogene (NASDAQ:NGNE) in a research report released on Thursday, MarketBeat Ratings reports. The firm issued an outperform rating and a $65.00 price objective on the stock.

Several other equities analysts also recently weighed in on NGNE. HC Wainwright reiterated a buy rating and issued a $51.00 target price on shares of Neurogene in a research note on Thursday, June 20th. William Blair began coverage on shares of Neurogene in a research note on Thursday, March 21st. They issued an outperform rating and a $61.00 target price for the company. Leerink Partnrs reaffirmed an outperform rating on shares of Neurogene in a report on Monday, April 29th. Baird R W raised shares of Neurogene to a strong-buy rating in a report on Tuesday, June 11th. Finally, SVB Leerink began coverage on shares of Neurogene in a report on Monday, April 29th. They set an outperform rating and a $46.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Neurogene has an average rating of Buy and an average target price of $51.33.

Neurogene Price Performance

NASDAQ NGNE opened at $36.39 on Thursday. The stock’s 50-day moving average is $33.95. Neurogene has a 52-week low of $12.20 and a 52-week high of $53.00.

Neurogene (NASDAQ:NGNE) last posted its earnings results on Friday, May 10th. The company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.03. On average, equities research analysts anticipate that Neurogene will post -4.15 EPS for the current year.

Hedge Funds Weigh In On Neurogene

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Great Point Partners LLC purchased a new position in Neurogene in the 4th quarter worth approximately $19,268,000. Vanguard Group Inc. grew its stake in Neurogene by 906.5% in the 1st quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock worth $25,831,000 after buying an additional 457,062 shares in the last quarter. Avidity Partners Management LP purchased a new position in Neurogene in the 4th quarter worth approximately $9,036,000. Baker BROS. Advisors LP grew its stake in Neurogene by 0.6% in the 1st quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company’s stock worth $23,211,000 after buying an additional 2,499 shares in the last quarter. Finally, BML Capital Management LLC purchased a new position in Neurogene in the 4th quarter worth approximately $478,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.